Matthew D. Tandy, PhD
Matthew D. Tandy, PhD,* mtandy@xenon-pharma.com, is associate director of chemistry, manufacturing, and control; Xenon Pharmaceuticals Inc., 200-3650 Gilmore Way, Burnaby, BC, Canada.
*to whom all correspondence should be addressed.
Articles
Using Modified QbD to Develop a Novel Pediatric Formulation of Ezogabine
March 3rd 2021The epilepsy treatment, Potiga, has been used off-label to treat specific types of epilepsy in some children. However, it has never been formally evaluated in pediatric clinical trials. Using a modified QbD approach, the authors have developed a granular formulation suitable for use in clinical trials involving infants and children.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: August 21st 2024 | Updated: December 26th 2024
Pharmaceutical Technology Editorial Advisory Board
Published: November 25th 2024 | Updated: December 26th 2024
Leveraging Integrated Patient-Centric Innovations When Developing Today’s Biologics
Published: December 20th 2024 | Updated: December 26th 2024
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Published: February 23rd 2024 | Updated: December 26th 2024
Europa Perspectives: Helping to Navigate the Regulatory System
